case_images: PMC11769826_01
case_images: Progression of the dermatological condition over time. (A) December 9: Initial presentation of lesions. (B) December 14: Progression with increased scaling and erythema. (C) December 18: Further deterioration, with prominent desquamation and ulceration. (D) December 25: Partial healing with residual hyperpigmentation and scarring.
case_images: fonc-14-1417936-g001.jpg
case_images: PMC11769826_01_fonc-14-1417936-g001.jpg
case_images: f1
case_images: TEN was made ( Figure 1A ). Treatment included intravenous administration of methylprednisolone 80 mg for 3 days (12.09-12.11). The methylprednisolone dose was adjusted to 500 mg intravenously for 4 days (12.14-12.17) ( Figure 1B ). By December 18, 2023, no new rashes were observed, blister leakage was reduced compared to before, some skin lesions began to scab, and the methylprednisolone dose was adjusted to 200 mg intravenously (12.18-12.21), with the addition of nystatin mouthwash for fungal infection prevention ( Figure 1C ). The methylprednisolone dosage was reduced to 80 mg for two days ( Figure 1D ).
case_images: (We have corrected the image to reflect the appropriate y-axis label as 'Dose' and updated the title to 'The variation in steroid dosage during hospitalization.) Variation in steroid dosage during hospitalization. The graph illustrates the changes in daily steroid dosage (mg) administered to the patient from December 9, 2023, to December 26, 2023. A rapid increase in dosage is observed from December 12 to December 14, reaching a peak on December 15-17, followed by a gradual tapering from December 18 onwards.
case_images: fonc-14-1417936-g002.jpg
case_images: PMC11769826_01_fonc-14-1417936-g002.jpg
case_images: f2
case_images: After discharge, methylprednisolone was switched to oral prednisone 60 mg and gradually tapered over 30 days ( Figure 2 ).
case_images: (We have updated the images to replace the previously submitted ones, ensuring that all patient information is properly concealed to protect privacy.) Changes in target lesion during treatment. (A, B) CT scan before treatment. (C, D) CT scan after 1 cycles of treatment. he red arrows mark the target lesions. The red box marks the target lesions.
case_images: fonc-14-1417936-g003.jpg
case_images: PMC11769826_01_fonc-14-1417936-g003.jpg
case_images: f3
case_images: Figure 3 ), blood routine, liver and kidney function, electrolytes, and other parameters revealed no significant abnormalities. Furthermore, detection of tumor treatment-related immune cells and Th1/Th2 subsets was performed ( Figure 4 ).
case_images: Analysis of immune cell counts and cytokine profiles related to tumor therapy. (A) Enumeration of immune cells relevant to tumor therapy, including NK cells, Lymphocytes, Total T lymphocytes, B lymphocytes, Helper T cells, and Cytotoxic T cells, comparing normal levels with patient levels on November 20, 2023, and December 13, 2023. (B) Detection of Th1/Th2 subsets, highlighting the levels of IL-2 (Th1), TNF-alpha (Th1), TNF-gamma (Th1), IL-4 (Th2), IL-6 (Th2), and IL-10 (Th2) in normal controls and in the patient on November 20, 2023, and December 13, 2023.
case_images: fonc-14-1417936-g004.jpg
case_images: PMC11769826_01_fonc-14-1417936-g004.jpg
case_images: f4
case_images: Figure 3 ), blood routine, liver and kidney function, electrolytes, and other parameters revealed no significant abnormalities. Furthermore, detection of tumor treatment-related immune cells and Th1/Th2 subsets was performed ( Figure 4 ).